Expansion Funding Beyond Air has secured up to $32 million in recent financing to support accelerated deployment of its flagship LungFit PH nitric oxide system, indicating readiness for increased sales activities and market penetration.

Strategic Partnerships The company is actively partnering with academic and healthcare institutions like Hebrew University of Jerusalem and Trillamed LLC, creating opportunities to collaborate on innovative treatments and expand its clinical application portfolio.

Market Deployment Deployment of LungFit PH systems at military and hospital facilities, including the U.S. Naval Hospital Guam and NICUs, highlights strong demand in medical and critical care markets ripe for expanded product offerings.

Research & Innovation Beyond Air's active research into ASD treatments and development of selective nNOS inhibitors suggest avenues for new medical device and drug development, opening possibilities for bundled or complementary sales.

Revenue & Growth Potential With current revenues between $1 million and $10 million and a focus on expanding deployment, there is significant upside for sales growth as the company increases its market footprint in respiratory and neurological therapies.